Note: Ingredients listed on restricted chemical lists
EC/CAS
25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
>=20-<30
EC/CAS
14807-96-6
Name of the chemical
Talc
Concentration
>=1-<5
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
>=1-<5
General Information
Version
2.1
Revision date
2025-08-25
Product name
Jentadueto extended-release tablets
Product Synonyms
Jentadueto® extended-release tablets 2.5/750 mg, 2.5/1000 mg and 5/1000 mg; Trayenta Duo® extended-release tablets 2.5/750 mg, 2.5/1000 mg and 5/1000 mg; Trajenta Duo® ex- tended-release tablets 2.5/750 mg, 2.5/1000 mg and 5/1000 mg with active ingredient: Linagliptin and Metformin hydrochloride
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user
supplier name
Boehringer Ingelheim Pharmaceuticals Inc
Emergency telephone
+1 703-527-3887, +1 703-741-5970
Icons in SDS
Company Information
company name
Boehringer Ingelheim Pharmaceuticals Inc
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
2.3 Other hazards
This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet). This product does not contain titanium dioxide in its respirable form and would not be considered carcinogenic; however, upon crushing, grinding or other processing that could result in the gener- ation of respirable particulates, the Category 2 carcinogenic classification would apply.
Signal word
Warning
Hazard statements
H319 Causes serious eye irritation.
Prevention
P264 Wash skin thoroughly after handling. P280 Wear eye protection/ face protection.
Response
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 If eye irritation persists: Get medical advice/ atten- tion.
2.1 Classification of the substance or mixture
1910.1200) Hazards for the product as supplied Eye irritation : Category 2A Other hazards This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet). This product does not contain titanium dioxide in its respirable form and would not be considered carcinogenic; however, upon crushing, grinding or other processing that could result in the gener- ation of respirable particulates, the Category 2 carcinogenic classification would apply.
